Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.

Aime S, Caravan P.

J Magn Reson Imaging. 2009 Dec;30(6):1259-67. doi: 10.1002/jmri.21969. Review.

2.

Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).

Sato T, Ito K, Tamada T, Kanki A, Watanabe S, Nishimura H, Tanimoto D, Higashi H, Yamamoto A.

Magn Reson Imaging. 2013 Oct;31(8):1412-7. doi: 10.1016/j.mri.2013.03.025. Epub 2013 Apr 30.

PMID:
23643157
3.

Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.

Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, Sieber MA.

Invest Radiol. 2009 Apr;44(4):226-33. doi: 10.1097/RLI.0b013e3181998eb7.

PMID:
19252439
4.

A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.

Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ.

Invest Radiol. 2008 Jan;43(1):65-75.

PMID:
18097279
5.

Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents.

Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA.

Eur Radiol. 2009 Jun;19(6):1417-24. doi: 10.1007/s00330-008-1259-4. Epub 2009 Jan 24.

PMID:
19169690
6.

Role of thermodynamic and kinetic parameters in gadolinium chelate stability.

Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C.

J Magn Reson Imaging. 2009 Dec;30(6):1249-58. doi: 10.1002/jmri.21967.

PMID:
19938037
7.

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.

Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.

AJR Am J Roentgenol. 2008 Apr;190(4):1060-8. doi: 10.2214/AJR.07.2822.

PMID:
18356456
8.
9.

The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.

Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J.

Exp Toxicol Pathol. 2009 Nov;61(6):537-52. doi: 10.1016/j.etp.2008.11.004. Epub 2009 Jan 7.

PMID:
19131226
10.

Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.

Abraham JL, Thakral C.

Eur J Radiol. 2008 May;66(2):200-7. doi: 10.1016/j.ejrad.2008.01.026. Review.

PMID:
18374532
11.

Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.

Sanyal S, Marckmann P, Scherer S, Abraham JL.

Nephrol Dial Transplant. 2011 Nov;26(11):3616-26. doi: 10.1093/ndt/gfr085. Epub 2011 Mar 25. Review.

12.

The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ.

Magn Reson Med. 2010 Nov;64(5):1274-80. doi: 10.1002/mrm.22553.

13.

Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.

Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée JM, Corot C.

Toxicol Sci. 2013 Jan;131(1):259-70. doi: 10.1093/toxsci/kfs274. Epub 2012 Sep 12. Erratum in: Toxicol Sci. 2013 Mar;132(1):252.

14.

Nephrogenic systemic fibrosis: more questions and some answers.

Morcos SK, Thomsen HS.

Nephron Clin Pract. 2008;110(1):c24-31; discussion c32. doi: 10.1159/000151228. Epub 2008 Aug 7. Review.

15.
16.

Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?

Weinreb JC, Abu-Alfa AK.

J Magn Reson Imaging. 2009 Dec;30(6):1236-9. doi: 10.1002/jmri.21979.

PMID:
19938035
17.

Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.

Broome DR.

Eur J Radiol. 2008 May;66(2):230-4. doi: 10.1016/j.ejrad.2008.02.011. Epub 2008 Mar 26. Review.

PMID:
18372138
18.

Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.

Kuo PH.

J Am Coll Radiol. 2008 Jan;5(1):29-35. doi: 10.1016/j.jacr.2007.08.014. Review.

PMID:
18180006
19.

Extracellular gadolinium contrast agents: differences in stability.

Morcos SK.

Eur J Radiol. 2008 May;66(2):175-9. doi: 10.1016/j.ejrad.2008.01.025. Epub 2008 Mar 14. Review.

PMID:
18343072
20.

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H.

Eur Radiol. 2008 Oct;18(10):2164-73. doi: 10.1007/s00330-008-0977-y. Epub 2008 Jun 11.

PMID:
18545998
Items per page

Supplemental Content

Write to the Help Desk